EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Renal cell carcinoma management: real-world practice and challenges at a national level

Marwan Ghosn iD, Joseph Kattan iD, Fadi El Karak iD, Hady Ghanem iD, Jamil Debs, Khaled Ibrahim, Ali Shamseddine iD

Future Oncology · 2023

DOI: 10.2217/fon-2021-1189 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Oncology, 2023. Verfasst von Marwan Ghosn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology Department, Saint Joseph University, Beirut, Lebanon. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) management has seen a revolution over the last decades. Six Lebanese oncologists discussed recent updates in RCC management and outlined the challenges and future directions in Lebanon. Sunitinib continues to be a first-line choice for metastatic RCC in Lebanon, except for intermediate- and poor-risk patients. Immunotherapy is not always accessible to patients or selected routinely as first-line therapy. More data are needed on the sequencing of immunotherapy and tyrosine kinase inhibitor treatments and on the use of immunotherapy beyond progression and/or after failure of immunotherapy in the first-line setting. For second-line management, the clinical experience with axitinib for low tumor growth rate and nivolumab after progression on tyrosine kinase inhibitors make those two agents the most widely used. Several challenges affect the Lebanese practice, limiting the accessibility and availability of the medications. Reimbursement remains the most critical challenge, especially with the socioeconomic crisis of October 2019.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansSunitinibAxitinibNivolumab

Stichwörter der Autor:innen

checkpoint inhibitorscombinationimmunotherapyrenal cell carcinomatyrosine kinase inhibitors

Substanzen

SunitinibAxitinibNivolumab

Autor:innen und Institutionen

  • Hematology-Oncology Department, Saint Joseph University, Beirut, Lebanon.
  • Hematology-Oncology Department, Hotel-Dieu de France University Hospital, Saint-Joseph University, Beirut, Lebanon.
  • Hematology-Oncology Division, Lebanese American University Medical Center - Rizk Hospital, Beirut, Lebanon.
  • Pfizer, Beirut, Lebanon.
  • Hematology-Oncology Division, Hammoud Hospital University Medical Center, Saida, Lebanon.
  • Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon.

ORCID-Profile: Marwan Ghosn, Joseph Kattan, Fadi El Karak, Hady Ghanem, Ali Shamseddine

Förderung

  • Pfizer

Zitieren

APA

Ghosn, M., Kattan, J., Karak, F. E., Ghanem, H., Debs, J., Ibrahim, K., & Shamseddine, A. (2023). Renal cell carcinoma management: real-world practice and challenges at a national level. Future Oncology. https://doi.org/10.2217/fon-2021-1189

Vancouver

Ghosn M, Kattan J, Karak FE, Ghanem H, Debs J, Ibrahim K, et al. Renal cell carcinoma management: real-world practice and challenges at a national level. Future Oncology. 2023. doi:10.2217/fon-2021-1189

BibTeX
@article{Ghosn2023,
  author = {Ghosn, Marwan and Kattan, Joseph and Karak, Fadi El and Ghanem, Hady and Debs, Jamil and Ibrahim, Khaled and Shamseddine, Ali},
  title = {Renal cell carcinoma management: real-world practice and challenges at a national level},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2021-1189}
}
Kostenlos starten →